HSDT - Helius Medical Technologies, Inc.
| Previous Close | 0.4500 |
| Open | 0.4670 |
| Bid | 0.4351 x 1000 |
| Ask | 0.4399 x 1000 |
| Day's Range | 0.4180 - 0.4670 |
| 52 Week Range | 0.2800 - 9.9300 |
| Volume | 37,959 |
| Avg. Volume | 81,192 |
| Market Cap | 11M |
| Beta (5Y Monthly) | -0.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3750 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.12 |
- American City Business Journals
Bucks County medical technology company raises capital to support product development, sales
A Bucks County neurotechnology company expects to raise $1.7 million from a public stock offering. Helius Medical Technologies Inc. (NASDAQ:HSDT) is selling 4.8 million shares of its common stock at $0.35 per share. The PoNS device, being developed initially as a treatment for balance disorders in traumatic brain injury patients, works by delivering neurostimulation through the tongue — which contains thousands of nerve fibers.
- GlobeNewswire
Helius Medical Technologies, Inc. Announces Pricing of Public Offering
The gross proceeds to Helius from this offering are expected to be approximately $1.7 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the securities in the offering will be sold by Helius. The offering is expected to close on or about November 26, 2019, subject to customary closing conditions including the approval of the Toronto Stock Exchange.
- GlobeNewswire
Helius Medical Technologies, Inc. Announces Proposed Public Offering
All of the securities in the offering will be sold by Helius. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
- GlobeNewswire
Helius Medical Technologies, Inc. Announces Addition of P3 Health As New Authorized PoNS Treatment™ Clinic in Toronto, Canada
P3 Health is a leading healthcare facility located in downtown Toronto’s St. Lawrence Market area at 145 Front Street East Suite G2 Toronto, Ontario Canada M5A 1E3. Since the opening of the first certified clinic, Neurotherapy Montreal, in December 2018, the Company has made it a priority to make the PoNS accessible to Canadians from coast-to-coast.
- Simply Wall St.
Did Changing Sentiment Drive Helius Medical Technologies's (NASDAQ:HSDT) Share Price Down A Painful 94%?
Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...
- Benzinga
The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...
- Zacks
Helius Medical Technologies, Inc. (HSDT) Reports Q3 Loss, Misses Revenue Estimates
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 0.00% and -50.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Helius Medical Technologies, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update; Updates Full Year 2019 Outlook
NEWTOWN, Pa., Nov. 12, 2019 -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness,.
- GlobeNewswire
Helius Medical Technologies, Inc. Announces Update on US Regulatory Strategy Following Pre-Submission Meeting with FDA
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today is providing an update outlining the Company’s US regulatory strategy following its pre-submission meeting with the U.S. Food and Drug Administration (“FDA”). Mr. Deschamps continued, “We thank FDA for their feedback on our plans during the recent pre-submission meeting and look forward to further collaboration with the Agency as we prepare our new de novo submission.
- GlobeNewswire
Helius Medical Technologies to Release Third Quarter of Fiscal Year 2019 Financial Results on November 12, 2019
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that third quarter of fiscal year 2019 financial results will be released before the market opens on Tuesday, November 12th. A live webcast of the call will also be provided on the Events section of the Company's investor relations website at https://event.on24.com/wcc/r/2079936/B1A21ECCA04BFBE67C9C9E27C2869A30. The webcast will be archived on the Events section of the Company’s investor relations website.
- GlobeNewswire
Helius Medical Technologies, Inc. and HealthTech Connex Announce Grand Opening of Canada’s Fifth PoNS Treatment™ Clinic
Helius Medical Technologies, Inc. and HealthTech Connex, leading providers of innovative neurological health solutions, announce the grand opening of Apollo Physical Therapy Centre (“Apollo”), Canada’s fifth clinic to offer the groundbreaking PoNS Treatment™ featuring the non-invasive PoNS™ (Portable Neuromodulation Stimulator) device.
- Simply Wall St.
What's The Outlook For Loss-Making Helius Medical Technologies, Inc. (NASDAQ:HSDT)?
Helius Medical Technologies, Inc. (NASDAQ:HSDT) continues its loss-making streak, announcing negative earnings for its...
- ACCESSWIRE
The MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin TX.
Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's inaugural ...
- GlobeNewswire
Helius Medical Technologies, Inc. Announces Addition of a New PoNS™ Clinic in Quebec City, Canada
NEWTOWN, Pa., Sept. 13, 2019 -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness,.
- ACCESSWIRE
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Helius Medical Technologies, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 9, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ:HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between November 9, 2017 and April 10, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 9, 2019.
- ACCESSWIRE
FINAL DEADLINE - Helius Medical Technologies, Inc. (HSDT) - Bronstein, Gewirtz & Grossman, LLC Announces Class Action and Lead Deadline: September 9, 2019
NEW YORK, NY / ACCESSWIRE / September 9, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ:HSDT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Helius securities from November 9, 2017 and April 10, 2019, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
- GlobeNewswire
MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Helius Medical Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ: HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
- ACCESSWIRE
HSDT FINAL SEPT. 9 DEADLINE, ROSEN, A TOP RANKED LAW FIRM, Reminds Helius Medical Technologies, Inc. Investors of Important Monday Deadline in Securities Class Action - HSDT
NEW YORK, NY / ACCESSWIRE / September 8, 2019 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Helius Medical Technologies, Inc. (NASDAQ:HSDT) from November ...
- ACCESSWIRE
MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Helius Medical Technologies, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 7, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ:HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between November 9, 2017 and April 10, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 9, 2019.
- ACCESSWIRE
HSDT SEP. 9 DEADLINE: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Helius Medical Technologies, Inc. - HSDT
NEW YORK, NY / ACCESSWIRE / September 6, 2019 / Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Helius Medical Technologies, Inc. (NASDAQ:HSDT) ...
- ACCESSWIRE
FINAL DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Helius Medical Technologies, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 6, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ:HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between November 9, 2017 and April 10, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 9, 2019.
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Helius Medical Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline - HSDT
Pomerantz LLP announces that a class action lawsuit has been filed against Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ: HSDT) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and indexed under 19-cv-07171, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise Helius securities between November 9, 2017, and April 10, 2019, inclusive (the “Class Period”), seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”). If you are a shareholder who purchased Helius securities during the class period, you have until September 9, 2019, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980.
- ACCESSWIRE
4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Helius Medical Technologies, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 5, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ:HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between November 9, 2017 and April 10, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 9, 2019.
